Ernexa Therapeutics (NASDAQ:ERNA) Raised to Hold at Zacks Research

Ernexa Therapeutics (NASDAQ:ERNA) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other equities analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Ernexa Therapeutics to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Tuesday, April 21st. Finally, Brookline Capital Markets started coverage on shares of Ernexa Therapeutics in a research report on Thursday, May 7th. They set a “buy” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Ernexa Therapeutics currently has an average rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Stock Performance

Shares of ERNA stock opened at $12.01 on Monday. The stock’s 50-day moving average is $5.99 and its two-hundred day moving average is $20.68. Ernexa Therapeutics has a 1 year low of $3.18 and a 1 year high of $100.46. The firm has a market cap of $14.00 million, a price-to-earnings ratio of -0.46 and a beta of 1.88.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its earnings results on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter. As a group, research analysts predict that Ernexa Therapeutics will post -9.38 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent SEC filing. 70.55% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Ernexa Therapeutics

Here are the key news stories impacting Ernexa Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets reiterated a Buy rating on Ernexa Therapeutics and maintained a $30 price target, while also publishing multi-year EPS estimates that suggest continued analyst attention on the name. Brookline Capital Markets earnings estimates
• Positive Sentiment: The company also released a virtual investor KOL Connect segment focused on the ovarian cancer market and its lead candidate ERNA-101, which may be supporting speculative interest in the stock. Investor KOL Connect segment
• Neutral Sentiment: Ernexa reported quarterly EPS of ($6.95), which was far worse than analyst expectations of ($1.95). That is fundamentally negative, but the market appears to be focusing more on trading momentum and analyst optimism than on the earnings miss. Earnings results
• Neutral Sentiment: ERNA was repeatedly placed on LULD pause halts during the morning session, indicating extreme volatility and heavy trading rather than a single new fundamental development. Trading halts
• Negative Sentiment: The earnings report showed a large miss versus consensus, which would normally pressure the stock and highlights the company’s still-significant losses. Earnings miss

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.